Avalo Therapeutics, Inc.

AVTX
$13.03 (+ $0.13 + 1.01%)
Last updated: 2026-06-10 18:26 UTC
AVTX Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS05338F3064
CUSIP05338F306
Market Price13.03
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-13.42
Market Cap$338.6M
Book Value5.13
Price to Book3.636
Beta0.86
52w High20.72
52w Low3.39
Next Earnings DateN/A

Avalo Therapeutics, Inc. trades under ticker AVTX on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US05338F3064, CUSIP 05338F306.

About the Company
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Price History